ONCOARENDI THERAP ZY-01

Research ONCOARENDI THERAP ZY-01 (1B1) on Bullrun: market cap EUR 29.52M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker1B1
• ExchangeF
• CountryPoland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 29.52M
• Financial periodFY2023
• RevenuePLN 3.65M
• Revenue growth-51.4%
• Net income-PLN 28.37M

Valuation Snapshot

latest market cap is EUR 29.52M.

About ONCOARENDI THERAP ZY-01

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH.

Frequently asked questions

What is ONCOARENDI THERAP ZY-01's market cap?

ONCOARENDI THERAP ZY-01's market capitalization is EUR 29.52M.

What does ONCOARENDI THERAP ZY-01 do?

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland.